(Q52355106)

English

Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients.

scientific article published on 5 January 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients. (English)

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

chronic myeloid leukemia

0 references

Francesco Albano

15

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Nicoletta Coccaro

object named as

Nicoletta Coccaro

7

0 references

Crescenzio Francesco Minervini

object named as

Crescenzio Francesco Minervini

3

0 references

Giorgina Specchia

14

object named as

Giorgina Specchia

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

author name string

Cosimo Cumbo

1

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Luciana Impera

2

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Paola Orsini

4

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Luisa Anelli

5

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Antonella Zagaria

6

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Giuseppina Tota

8

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Angela Minervini

9

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Paola Casieri

10

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Claudia Brunetti

11

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Antonella Russo Rossi

12

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Elisa Parciante

13

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

language of work or name

0 references

publication date

5 January 2018

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

9

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

13

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

10978-10986

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Discontinuation of TKI therapy and 'functional' cure for CML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Oxford Nanopore MinION Sequencing and Genome Assembly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Standardized definitions of molecular response in chronic myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

22 May 2018

Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

13 August 2018

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

13 August 2018

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

13 August 2018

Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

13 August 2018

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

13 August 2018

A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

13 August 2018

Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

30 November 2018

“Home-brew” FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834283

30 November 2018

Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/29541390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29541390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.18632/ONCOTARGET.23971

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

29 April 2018

http://europepmc.org/abstract/PMC/5834283

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52355106&oldid=1620484543"